An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily For 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis.
Latest Information Update: 19 Jan 2021
At a glance
- Drugs Linzagolix (Primary)
- Indications Dysmenorrhoea; Dyspareunia; Endometriosis
- Focus Therapeutic Use
- Sponsors ObsEva
- 19 Jan 2021 New trial record